NCT03318445 - Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 12, 2018

Primary Completion Date

March 1, 2021

Study Completion Date

March 1, 2021

Conditions

Solid Tumor, Unspecified, Adult

Interventions

DRUG

Rucaparib

All participants will take rucaparib by mouth

DRUG

Irinotecan

Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.

Trial Locations (1)

94143

University of California San Francisco, San Francisco